Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies

MLA

Zinzani, Pier Luigi, et al. “Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies.” Blood, vol. 134, no. 1, Number 1 Supplement 1, Nov. 2019, p. 4009. EBSCOhost, https://doi.org/10.1182/blood-2019-131779.

APA

Zinzani, P. L., Santoro, A., Mollica, L., Leppä, S., Follows, G. A., Lenz, G., Kim, W. S., Nagler, A., Panayiotidis, P., Demeter, J., Morschhauser, F., Munoz, J., Miriyala, A., Benson, A., Garcia-Vargas, J., Childs, B. H., & Dreyling, M. (2019). Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies. Blood, 134(1, Number 1 Supplement 1), 4009. https://doi.org/10.1182/blood-2019-131779

Chicago

Zinzani, Pier Luigi, Armando Santoro, Luigina Mollica, Sirpa Leppä, George A Follows, Georg Lenz, Won Seog Kim, et al. 2019. “Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies.” Blood 134 (1, Number 1 Supplement 1): 4009. doi:10.1182/blood-2019-131779.